| Substance | Condition | Seq | Src | PMID | Dtl | Title |
| Astragalosides | Acute Kidney Injury | 1 | PM | 38494585 | 📋 | Research progress of astragaloside IV in treating acute kidney injury |
| Astragalosides | Acute Kidney Injury | 2 | PM | 33148504 | 📋 | Altered metabolic profiles and biomarkers associated with astragaloside IV-mediated protection against cisplatin-induced acute kidney injury in rats: An HPLC-TOF/MS-based untargeted metabolomics study |
| Astragalosides | Acute Kidney Injury | 3 | PM | 28871521 | 📋 | Astragaloside-IV Prevents Acute Kidney Injury and Inflammation by Normalizing Muscular Mitochondrial Function Associated With a Nitric Oxide Protective Mechanism in Crush Syndrome Rats |
| Astragalosides | Acute Kidney Injury | 8 | PM | 28750561 | 📋 | Renoprotective mechanisms of Astragaloside IV in cisplatin-induced acute kidney injury |
| Astragalosides | Acute Kidney Injury | 7 | PM | 23853656 | 📋 | Preventive Effects of a Natural Anti-Inflammatory Agent, Astragaloside IV, on Ischemic Acute Kidney Injury in Rats |
| Astragalosides | Acute Kidney Injury | 6 | PM | 23325448 | 📋 | Astragaloside IV prevents acute kidney injury in two rodent models by inhibiting oxidative stress and apoptosis pathways |
| Astragalosides | Aging Kidney | 2 | PM | 37088750 | 📋 | [Effects of astragaloside IV on delaying kidney aging and its mechanisms] |
| Astragalosides | Aging Kidney | 1 | PM | 36561604 | 📋 | Study on the Mechanism of Radix Astragali against Renal Aging Based on Network Pharmacology |
| Astragalosides | Chronic Renal Failure | 3 | PM | 37033627 | 📋 | Astragaloside IV alleviates 1-deoxysphinganine-induced mitochondrial dysfunction during the progression of chronic kidney disease through p62-Nrf2 antioxidant pathway |
| Astragalosides | Chronic Renal Failure | 2 | PM | 36764562 | 📋 | Astragaloside IV attenuates indoxyl sulfate-induced injury of renal tubular epithelial cells by inhibiting the aryl hydrocarbon receptor pathway |
| Astragalosides | Chronic Renal Failure | 1 | PM | 33405354 | 📋 | Formononetin ameliorates muscle atrophy by regulating myostatin-mediated PI3K/Akt/FoxO3a pathway and satellite cell function in chronic kidney disease |
| Astragalosides | Diabetic Nephropathy | 40 | PM | 38572426 | 📋 | Astragaloside IV attenuates renal tubule injury in DKD rats via suppression of CD36-mediated NLRP3 inflammasome activation |
| Astragalosides | Diabetic Nephropathy | 39 | PM | 38389170 | 📋 | Astragaloside IV Mitigated Diabetic Nephropathy by Restructuring Intestinal Microflora and Ferroptosis |
| Astragalosides | Diabetic Nephropathy | 38 | PM | 37751175 | 📋 | Astragaloside IV Inhibited Podocyte Pyroptosis in Diabetic Kidney Disease by Regulating SIRT6/HIF-1α Axis |
| Astragalosides | Diabetic Nephropathy | 28 | PM | 37261217 | 📋 | Astragaloside IV Attenuates High-Glucose-Induced Impairment in Diabetic Nephropathy by Increasing Klotho Expression via the NF- κ B/NLRP3 Axis |
| Astragalosides | Diabetic Nephropathy | 27 | PM | 37189016 | 📋 | Astragaloside IV attenuates high glucose-induced NF-κB-mediated inflammation through activation of PI3K/AKT-ERK-dependent Nrf2/ARE signaling pathway in glomerular mesangial cells |
| Astragalosides | Diabetic Nephropathy | 26 | PM | 37150034 | 📋 | The beneficial effects of astragaloside IV on ameliorating diabetic kidney disease |
| Astragalosides | Diabetic Nephropathy | 25 | PM | 37030337 | 📋 | Astragaloside IV attenuates podocyte apoptosis through ameliorating mitochondrial dysfunction by up-regulated Nrf2-ARE/TFAM signaling in diabetic kidney disease |
| Astragalosides | Diabetic Nephropathy | 24 | PM | 35669284 | 📋 | Astragaloside IV Alleviates Renal Tubular Epithelial-Mesenchymal Transition via CX3CL1-RAF/MEK/ERK Signaling Pathway in Diabetic Kidney Disease |
| Astragalosides | Diabetic Nephropathy | 23 | PM | 35510516 | 📋 | Mitogen-activating protein kinase kinase kinase kinase-3, inhibited by Astragaloside IV through H3 lysine 4 monomethylation, promotes the progression of diabetic nephropathy by inducing apoptosis |
| Astragalosides | Diabetic Nephropathy | 22 | PM | 34278447 | 📋 | Astragaloside IV ameliorates diabetic nephropathy in db/db mice by inhibiting NLRP3 inflammasome‑mediated inflammation |
| Astragalosides | Diabetic Nephropathy | 21 | PM | 33796024 | 📋 | Astragaloside II Ameliorated Podocyte Injury and Mitochondrial Dysfunction in Streptozotocin-Induced Diabetic Rats |
| Astragalosides | Diabetic Nephropathy | 20 | PM | 33606151 | 📋 | Astragaloside IV inhibits palmitic acid-induced apoptosis through regulation of calcium homeostasis in mice podocytes |
| Astragalosides | Diabetic Nephropathy | 19 | PM | 33476631 | 📋 | Astragaloside IV protects against podocyte apoptosis by inhibiting oxidative stress via activating PPARγ-Klotho-FoxO1 axis in diabetic nephropathy |
| Astragalosides | Diabetic Nephropathy | 18 | PM | 32942018 | 📋 | Renal protective effects of astragaloside IV, in diabetes mellitus kidney damage animal models: A systematic review, meta-analysis |
| Astragalosides | Diabetic Nephropathy | 17 | PM | 32855769 | 📋 | Transcriptomic Analysis Reveals the Protection of Astragaloside IV against Diabetic Nephropathy by Modulating Inflammation |
| Astragalosides | Diabetic Nephropathy | 16 | PM | 32774716 | 📋 | Astragaloside IV alleviates puromycin aminonucleoside-induced podocyte cytoskeleton injury through the Wnt/PCP pathway |
| Astragalosides | Diabetic Nephropathy | 15 | PM | 32695006 | 📋 | Protective Effect and Possible Mechanisms of Astragaloside IV in Animal Models of Diabetic Nephropathy: A Preclinical Systematic Review and Meta-Analysis |
| Astragalosides | Diabetic Nephropathy | 1 | PM | 32339782 | 📋 | Astragaloside IV Acts Through Multi-Scale Mechanisms to Effectively Reduce Diabetic Nephropathy |
| Astragalosides | Diabetic Nephropathy | 8 | PM | 31805910 | 📋 | Astragaloside IV Protects Against Diabetic Nephropathy via Activating eNOS in Streptozotocin Diabetes-Induced Rats |
| Astragalosides | Diabetic Nephropathy | 7 | PM | 31572545 | 📋 | Astragaloside IV Inhibits Excessive Mesangial Cell Proliferation and Renal Fibrosis Caused by Diabetic Nephropathy via Modulation of the TGF-β1/Smad/miR-192 Signaling Pathway |
| Astragalosides | Diabetic Nephropathy | 12 | PM | 31086575 | 📋 | Astragaloside IV Ameliorates High Glucose-Induced HK-2 Cell Apoptosis and Oxidative Stress by Regulating the Nrf2/ARE Signaling Pathway |
| Astragalosides | Diabetic Nephropathy | 13 | PM | 30483732 | 📋 | Astragaloside IV Ameliorates High glucose‑induced Renal Tubular epithelial‑mesenchymal Transition by Blocking mTORC1/p70S6K Signaling in HK‑2 Cells |
| Astragalosides | Diabetic Nephropathy | 10 | PM | 30425453 | 📋 | Combination of Ginsenoside Rg1 and Astragaloside IV Reduces Oxidative Stress and Inhibits TGF-β1/Smads Signaling Cascade on Renal Fibrosis in Rats With Diabetic Nephropathy |
| Astragalosides | Diabetic Nephropathy | 4 | PM | 30233141 | 📋 | Astragaloside IV/lncRNA-TUG1/TRAF5 Signaling Pathway Participates in Podocyte Apoptosis of Diabetic Nephropathy Rats |
| Astragalosides | Diabetic Nephropathy | 6 | PM | 30122901 | 📋 | Astragaloside IV Improves Renal Function and Fibrosis via Inhibition of miR-21-induced Podocyte Dedifferentiation and Mesangial Cell Activation in Diabetic Mice |
| Astragalosides | Diabetic Nephropathy | 3 | PM | 29896981 | 📋 | Astragaloside IV Ameliorates Early Diabetic Nephropathy by Inhibition of MEK1/2-ERK1/2-RSK2 Signaling in Streptozotocin-Induced Diabetic Mice |
| Astragalosides | Diabetic Nephropathy | 9 | PM | 29792879 | 📋 | Astragaloside Suppresses Apoptosis of the Podocytes in Rats With Diabetic Nephropathy via miR-378/TRAF5 Signaling Pathway |
| Astragalosides | Diabetic Nephropathy | 2 | PM | 28767702 | 📋 | Astragaloside IV Ameliorates Diabetic Nephropathy by Modulating the Mitochondrial Quality Control Network |
| Astragalosides | Diabetic Nephropathy | 37 | PM | 28761152 | 📋 | Astragaloside IV protects against podocyte injury via SERCA2-dependent ER stress reduction and AMPKα-regulated autophagy induction in streptozotocin-induced diabetic nephropathy |
| Astragalosides | Diabetic Nephropathy | 5 | PM | 28066247 | 📋 | Astragaloside IV Attenuates Podocyte Apoptosis Mediated by Endoplasmic Reticulum Stress Through Upregulating Sarco/Endoplasmic Reticulum Ca 2+-ATPase 2 Expression in Diabetic Nephropathy |
| Astragalosides | Diabetic Nephropathy | 11 | PM | 27585918 | 📋 | Astragaloside IV Ameliorates Renal Injury in db/db Mice |
| Astragalosides | Diabetic Nephropathy | 34 | PM | 27313676 | 📋 | Effects of astragalosides from Radix Astragali on high glucose-induced proliferation and extracellular matrix accumulation in glomerular mesangial cells |
| Astragalosides | Diabetic Nephropathy | 14 | PM | 27109610 | 📋 | Astragaloside IV Prevents High Glucose-Induced Podocyte Apoptosis via Downregulation of TRPC6 |
| Astragalosides | Diabetic Nephropathy | 36 | PM | 26261569 | 📋 | Astragaloside effect on TGF-β1, SMAD2/3, and α-SMA expression in the kidney tissues of diabetic KKAy mice |
| Astragalosides | Diabetic Nephropathy | 35 | PM | 26125738 | 📋 | Effects of Astragaloside IV on diabetic nephropathy in rats |
| Astragalosides | Diabetic Nephropathy | 33 | PM | 25886386 | 📋 | Astragaloside IV attenuates proteinuria in streptozotocin-induced diabetic nephropathy via the inhibition of endoplasmic reticulum stress |
| Astragalosides | Diabetic Nephropathy | 29 | PM | 24718766 | 📋 | Astragaloside IV prevents damage to human mesangial cells through the inhibition of the NADPH oxidase/ROS/Akt/NF‑κB pathway under high glucose conditions |
| Astragalosides | Diabetic Nephropathy | 32 | PM | 23719694 | 📋 | Astragaloside IV attenuates glycated albumin-induced epithelial-to-mesenchymal transition by inhibiting oxidative stress in renal proximal tubular cells |
| Astragalosides | Diabetic Nephropathy | 30 | PM | 23434274 | 📋 | Astragaloside IV ameliorates renal injury in streptozotocin-induced diabetic rats through inhibiting NF-κB-mediated inflammatory genes expression |
| Astragalosides | Diabetic Nephropathy | 31 | PM | 22745830 | 📋 | Astragaloside IV, a novel antioxidant, prevents glucose-induced podocyte apoptosis in vitro and in vivo |
| Astragalosides | Glomerulonephritis | 2 | PM | 37529109 | 📋 | Astragaloside IV improves renal function and alleviates renal damage and inflammation in rats with chronic glomerulonephritis |
| Astragalosides | Glomerulonephritis | 1 | PM | 32726508 | 📋 | Protective role of Astragaloside IV in chronic glomerulonephritis by activating autophagy through PI3K/AKT/AS160 pathway |
| Astragalosides | Glomerulosclerosis | 1 | PM | 28066247 | 📋 | Astragaloside IV Attenuates Podocyte Apoptosis Mediated by Endoplasmic Reticulum Stress Through Upregulating Sarco/Endoplasmic Reticulum Ca 2+-ATPase 2 Expression in Diabetic Nephropathy |
| Astragalosides | IgA Nephropathy | 1 | PM | 33935780 | 📋 | Astragaloside IV Inhibits Galactose-Deficient IgA1 Secretion via miR-98-5p in Pediatric IgA Nephropathy |
| Astragalosides | Kidney Disease | 1 | PM | 37089929 | 📋 | Fufang shenhua tablet, astragali radix and its active component astragaloside IV: Research progress on anti-inflammatory and immunomodulatory mechanisms in the kidney |
| Astragalosides | Kidney Fibrosis | 11 | PM | 38850482 | 📋 | Mechanism of Astragaloside IV in Treatment of Renal Tubulointerstitial Fibrosis |
| Astragalosides | Kidney Fibrosis | 10 | PM | 38820434 | 📋 | Astragaloside IV alleviates renal fibrosis by inhibiting renal tubular epithelial cell pyroptosis induced by urotensin II through regulating the cAMP/PKA signaling pathway |
| Astragalosides | Kidney Fibrosis | 6 | PM | 37443810 | 📋 | Astragaloside IV Blunts Epithelial-Mesenchymal Transition and G2/M Arrest to Alleviate Renal Fibrosis via Regulating ALDH2-Mediated Autophagy |
| Astragalosides | Kidney Fibrosis | 5 | PM | 35840059 | 📋 | A network pharmacology-based study on the mechanism of astragaloside IV alleviating renal fibrosis through the AKT1/GSK-3β pathway |
| Astragalosides | Kidney Fibrosis | 4 | PM | 35643056 | 📋 | Astragaloside IV attenuated TGF-β1- induced epithelial-mesenchymal transition of renal tubular epithelial cells via connexin 43 and Akt/mTOR signaling pathway |
| Astragalosides | Kidney Fibrosis | 2 | PM | 31572545 | 📋 | Astragaloside IV Inhibits Excessive Mesangial Cell Proliferation and Renal Fibrosis Caused by Diabetic Nephropathy via Modulation of the TGF-β1/Smad/miR-192 Signaling Pathway |
| Astragalosides | Kidney Fibrosis | 1 | PM | 31497219 | 📋 | Astragaloside IV Attenuates Renal Fibrosis Through Repressing Epithelial-To-Mesenchymal Transition by Inhibiting microRNA-192 Expression: in vivo and in vitro Studies |
| Astragalosides | Kidney Fibrosis | 3 | PM | 27855303 | 📋 | Astragaloside IV From Astragalus Membranaceus Ameliorates Renal Interstitial Fibrosis by Inhibiting Inflammation via TLR4/NF-кB in Vivo and in Vitro |
| Astragalosides | Kidney Fibrosis | 9 | PM | 24951279 | 📋 | Astragaloside IV ameliorates renal fibrosis via the inhibition of mitogen-activated protein kinases and antiapoptosis in vivo and in vitro |
| Astragalosides | Kidney Fibrosis | 8 | PM | 24879422 | 📋 | Astragaloside IV inhibits renal tubulointerstitial fibrosis by blocking TGF-β/Smad signaling pathway in vivo and in vitro |
| Astragalosides | Kidney Fibrosis | 7 | PM | 21232035 | 📋 | Astragaloside IV synergizes with ferulic acid to inhibit renal tubulointerstitial fibrosis in rats with obstructive nephropathy |
| Astragalosides | Membranous Nephropathy | 1 | PM | 22086717 | 📋 | Astragaloside IV attenuates complement membranous attack complex induced podocyte injury through the MAPK pathway |
| Astragalosides | Nephrotoxicity | 5 | PM | 37931776 | 📋 | Investigation of the Metabolism of Astragaloside IV in a Puromycin-Damaged Rat Model by UPLC-Q-TOF-MS/MS Analysis |
| Astragalosides | Nephrotoxicity | 4 | PM | 37446560 | 📋 | Protective Effect of Astragaloside IV against Cadmium-Induced Damage on Mouse Renal Podocytes (MPC5) |
| Astragalosides | Nephrotoxicity | 3 | PM | 35370757 | 📋 | Therapeutic Potential of Astragaloside IV Against Adriamycin-Induced Renal Damage in Rats via Ferroptosis |
| Astragalosides | Nephrotoxicity | 1 | PM | 33536919 | 📋 | Astragaloside IV Alleviates Tacrolimus-Induced Chronic Nephrotoxicity via p62-Keap1-Nrf2 Pathway |
| Astragalosides | Nephrotoxicity | 2 | PM | 30176914 | 📋 | Effect of Astragaloside IV on Indoxyl Sulfate-Induced Kidney Injury in Mice via Attenuation of Oxidative Stress |
| Astragalosides | Proteinuria | 1 | PM | 33796024 | 📋 | Astragaloside II Ameliorated Podocyte Injury and Mitochondrial Dysfunction in Streptozotocin-Induced Diabetic Rats |
| Astragalosides | Proteinuria | 2 | PM | 30233141 | 📋 | Astragaloside IV/lncRNA-TUG1/TRAF5 Signaling Pathway Participates in Podocyte Apoptosis of Diabetic Nephropathy Rats |
| Astragalosides | Proteinuria | 3 | PM | 27585918 | 📋 | Astragaloside IV Ameliorates Renal Injury in db/db Mice |
| Astragalosides | Renal Ischemia-Reperfusion | 4 | PM | 38027853 | 📋 | Network pharmacology and in vitro experimental verification to reveal the mechanism of Astragaloside IV against kidney ischemia-reperfusion injury |
| Astragalosides | Renal Ischemia-Reperfusion | 2 | PM | 36675720 | 📋 | Astragaloside IV Targets Macrophages to Alleviate Renal Ischemia-Reperfusion Injury via the Crosstalk between Hif-1α and NF-κB (p65)/Smad7 Pathways |
| Astragalosides | Renal Ischemia-Reperfusion | 1 | PM | 36092836 | 📋 | Astragaloside IV protects against ischemia/reperfusion (I/R)-induced kidney injury based on the Keap1-Nrf2/ARE signaling pathway |
| Astragalosides | Renal Ischemia-Reperfusion | 3 | PM | 26770431 | 📋 | AS-IV protects against kidney IRI through inhibition of NF-κB activity and PUMA upregulation |
| Astragalosides | Septic Acute Kidney Injury | 4 | PM | 38237511 | 📋 | Astragaloside Ⅳ negatively regulates Gpr97-TPL2 signaling to protect against hyperhomocysteine-exacerbated sepsis associated acute kidney injury |
| Astragalosides | Septic Acute Kidney Injury | 1 | PM | 36056848 | 📋 | Astragaloside IV protects sepsis-induced acute kidney injury by attenuating mitochondrial dysfunction and apoptosis in renal tubular epithelial cells |
| Astragalosides | Septic Acute Kidney Injury | 2 | PM | 35859295 | 📋 | Protective effect of Astragalus membranaceus and Astragaloside IV in sepsis-induced acute kidney injury |
| Astragalosides | Septic Acute Kidney Injury | 3 | PM | 28328867 | 📋 | Astragaloside IV Alleviates Lipopolysaccharide-Induced Acute Kidney Injury Through Down-Regulating Cytokines, CCR5 and p-ERK, and Elevating Anti-Oxidative Ability |
